Artbio
Last verified 2026-05-16. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $243.0Mattributed |
|---|---|
| Latest round | series-b, $132.0M, 2025-07-01attributed |
| Founded | 2021 |
| Headquarters | Cambridge, USA |
| Industry | bio |
| Stage | series-b+ |
| Website | artbio.com |
ARTBIO develops alpha radioligand therapies that deliver targeted radiation directly to cancer cells. The therapies are designed for patients with solid tumors including prostate, non-small cell lung, pancreatic, and triple-negative breast cancers. It runs a proprietary Pb-212 isotope production platform spanning drug design, manufacturing.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-07-01 | series-b | $132.0M | undisclosed |
Detected tech stack
Netlify, Gatsby 4.25.9, React, Webpack
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $132.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $243.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | artbio.com, read 2026-05-16 |
| Description | self-reported | artbio.com, read 2026-05-16 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.